Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase I/II study of BNT3212 alone or with BNT327 in advanced solid tumors
CTR20253266Phase 2Active
- Sponsor
- Biotheus
- Start
- Sep 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of BNT3212, pumitamig in Nonhematologic neoplasms, sponsored by Biotheus. Started Sep 2025; status: active.
02
Drugs
BNT3212pumitamig
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20253266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253266.